From the company’s inception, GeneMind aimed at the research and development of the DNA sequencer: the core instrument of the modern molecular diagnostics. Genemind is committed to building a precision medical ecosystem that serves healthcare through collaborations with genetic testing service providers and medical institutions.
Human exonic regions account for only 1-2% of the whole genome, yet they contain about 85% of disease-causing mutations. Whole exome sequencing (WES) can significantly improve the detection rate of
On October 15, 2024, GeneMind hosted the “2024 Life Omics Innovation Ecosystem Conference and GeneMind New Product Launch” in Nanjing, Jiangsu province. With the theme “Sequencing Powerhouse: Unlocking the Genetic Potential”, the event
GeneMind has collaborated with QIAGEN to validate multiple mature NGS solutions from QIAGEN based on the GeneMind SURFSeq 5000* and GenoLab M* sequencing platforms. The test results demonstrate high compatibility between the GeneMind sequencing platforms and
*Unless otherwise informed, GeneMind sequencing platform and related sequencing reagents are not available in the USA, Canada, Australia, Japan, Singapore, Western Europe and Nordic countries yet.
